Scholar Rock (SRRK) to Release Quarterly Earnings on Tuesday

Scholar Rock (NASDAQ:SRRK) is expected to issue its Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect Scholar Rock to post earnings of ($0.86) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 3, 2026 at 8:00 AM ET.

Scholar Rock Trading Down 2.1%

SRRK opened at $47.01 on Tuesday. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. The firm has a market cap of $4.80 billion, a price-to-earnings ratio of -14.92 and a beta of 0.67. Scholar Rock has a 12 month low of $22.71 and a 12 month high of $49.82. The stock has a fifty day moving average price of $45.20 and a 200-day moving average price of $38.52.

Insider Buying and Selling

In related news, CEO David Hallal sold 57,450 shares of the stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total value of $2,453,115.00. Following the sale, the chief executive officer owned 1,541,645 shares in the company, valued at approximately $65,828,241.50. This trade represents a 3.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Akshay Vaishnaw sold 20,438 shares of Scholar Rock stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $42.70, for a total value of $872,702.60. Following the sale, the insider directly owned 595,767 shares of the company’s stock, valued at $25,439,250.90. This represents a 3.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 336,448 shares of company stock valued at $14,971,883 in the last three months. Insiders own 13.30% of the company’s stock.

Institutional Trading of Scholar Rock

Institutional investors and hedge funds have recently modified their holdings of the business. California State Teachers Retirement System grew its holdings in shares of Scholar Rock by 0.9% during the second quarter. California State Teachers Retirement System now owns 62,372 shares of the company’s stock worth $2,209,000 after purchasing an additional 577 shares in the last quarter. Osaic Holdings Inc. lifted its position in Scholar Rock by 25.1% during the fourth quarter. Osaic Holdings Inc. now owns 3,318 shares of the company’s stock valued at $146,000 after purchasing an additional 665 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Scholar Rock in the 4th quarter worth approximately $30,000. Summit Securities Group LLC bought a new position in shares of Scholar Rock in the 4th quarter worth $31,000. Finally, E Fund Management Co. Ltd. grew its position in Scholar Rock by 6.8% in the second quarter. E Fund Management Co. Ltd. now owns 11,146 shares of the company’s stock worth $395,000 after acquiring an additional 710 shares in the last quarter. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a research report on Thursday, December 11th. Barclays boosted their price objective on shares of Scholar Rock from $45.00 to $52.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. UBS Group began coverage on shares of Scholar Rock in a research note on Wednesday, January 7th. They issued a “buy” rating and a $60.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a research note on Thursday, January 22nd. Finally, HC Wainwright increased their price objective on shares of Scholar Rock from $44.00 to $58.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Four research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $51.14.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).